Elstar Therapeutics Inc.

Elstar Therapeutics brings a powerful new approach to generating multi-functional therapeutics with the potential to fulfill the promise of precision cancer immunotherapy and chart new directions in fighting immunological diseases. Armed with a platform that enables rapid production of multi-functional molecules effective in modulating a broad range of immunological processes, Elstars goal is to develop new medicines for life-threatening cancers and serious inflammatory diseases. Our Universal Targeted Immunotherapy (UniTI) platform uniquely positions Elstar to overcome barriers that have previously blocked many promising immunotherapeutic approaches. Elstar Therapeutics was founded by the veteran protein and antibody engineer Andreas Loew together with Apple Tree Partners (www.appletreepartners.com), a healthcare-focused venture capital firm based in New York City.